Abeona Therapeutics Inc. cash flow statement

In fiscal 2025, Abeona Therapeutics Inc.'s operations generated −$76.3m of cash; it spent $8.0m on capital projects, leaving free cash flow of −$84.3m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Abeona Therapeutics Inc.: cash flow statement, annual
Fiscal year	2010Dec 2010	2011Dec 2011	2012Dec 2012	2013Dec 2013	2014Dec 2014	2015Dec 2015	2016Dec 2016	2017Dec 2017	2018Dec 2018	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2025Dec 2025	LTMJun 2026
Cash from operations	−7	−8	−4	0	−2	−10	−13	−23	−39	−35	−66	−43	−37	−76	−76
Depreciation and amortisation	0	0	0	0	0	1	1	1	2	5	3	3	2	3	3
Stock-based pay	1	1	0	0	1	4	5	5	8	6	9	3	5	11	12
Capital spending	0	0	0	0	0	0	1	1	9	1	4	0	0	8	5
Free cash flow	−7	−8	−4	−0	−2	−11	−14	−24	−48	−36	−70	−44	−37	−84	−82
Free cash flow after stock pay	−8	−9	−4	−0	−3	−15	−18	−28	−57	−42	−79	−47	−42	−95	−93
Shares issued	13	6	—	0	0	7	—	—	—	—	8	13	14	17	—

US$ millions unless shown otherwise. Fiscal quarters.

Abeona Therapeutics Inc.: cash flow statement, quarterly
Quarter	2023 Q2Jun 2023	2023 Q3Sept 2023	2023 Q4Dec 2023	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026
Cash from operations	−10	−6	−9	−19	−21	−18	−20	−17
Depreciation and amortisation	1	1	0	1	1	1	1	1
Stock-based pay	1	2	2	3	3	3	3	3
Capital spending	0	0	0	3	3	1	1	0
Free cash flow	−10	−6	−9	−22	−24	−19	−21	−18
Free cash flow after stock pay	−11	−7	−11	−25	−26	−22	−24	−21
Shares issued	—	0	8	11	0	0	—	—

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: ABEO vs CRSP ABEO vs JANX ABEO vs STOK

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Abeona Therapeutics Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Abeona Therapeutics Inc.